Nothing to Sneeze at: CSL Scoops Up $1 Billion North Carolina Flu Vaccine Plant in $275 Million Novartis Deal

SUGAR LAND--October 29, 2014--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--With its offer of $275 million to purchase Novartis' influenza vaccine business, Australian drug maker CSL Limited has scored arguably one of the industry's biggest bargains. In addition to acquiring the existing Novartis influenza vaccine drug portfolio and development pipeline, the purchase will include the company's $1 billion vaccine plant in Holly Springs, North Carolina.

Within this article: Details on the acquisition and its potential to grow CSL.

Other companies featured: GlaxoSmithKline (NYSE:GSK), Eli Lilly and Company (NYSE:LLY)